RESEARCH ARTICLE

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV

Sonia Vibhakar Patel1, Dushyantha T. Jayaweera2, Keri N. Althoff3,†, Joseph J. Eron4,†, Janna Radtchenko5,†, Anthony Mills6,†, Graeme Moyle7, Steven Santiago8,†, Paul E. Sax9,‡, Jason Gillman10,‡, Karam Mounzer11,‡, Richard A. Elion12,*, Gregory D. Huhn13,‡

1 The Ruth M. Rothstein Core Center, Cook County Health, Chicago, Illinois, United States of America, 2 Division of Infectious Disease, Miller School of Medicine, University of Miami, Miami, Florida, United States of America, 3 Johns Hopkins University, Baltimore, Maryland, United States of America, 4 Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 5 Trio Health Analytics, La Jolla, California, United States of America, 6 Southern California Men's Medical Group, Los Angeles, California, United States of America, 7 Chelsea and Westminster Hospital, London, United Kingdom, 8 Care Resource, Miami, Florida, United States of America, 9 Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 10 Prism Health North Texas, Dallas, Texas, United States of America, 11 Perelman School of Medicine at The University of Pennsylvania and Philadelphia Fight Community Health Centers, Philadelphia, Pennsylvania, United States of America, 12 George Washington University School of Medicine, Washington, District of Columbia, United States of America, 13 The Ruth M. Rothstein Core Center and Rush University Medical Center, Chicago, Illinois, United States of America

*rickelion@gmail.com

These authors contributed equally to this work.
‡ These authors also contributed equally to this work.

Abstract

The advent of direct-acting antiviral (DAA) therapies has dramatically transformed HCV treatment, with most recent trials demonstrating high efficacy rates (>90%) across all genotypes and special populations, including patients with HIV/HCV coinfection. The efficacy rates of HCV treatment are nearly identical between patients with HCV monoinfection and patients with HIV/HCV coinfection; however, there are limited studies to compare real-world efficacy with efficacy observed in clinical trials. Using a database from HIV clinics across the United States (US), we identified 432 patients with HIV/HCV coinfection who completed DAA therapy from January 1, 2014 to March 31, 2017 and were assessed for efficacy. Efficacy was evaluated as sustained virologic response (SVR) 12 weeks after DAA completion; furthermore, factors associated with achieving SVR12 were identified. In this analysis, we found DAA therapies to be effective, with 94% of the patients achieving SVR12 and 6% experiencing virologic failure. Baseline variables, including older age, HCV viral load <800K IU/ML, FIB-4 score <1.45, absence of depression, diabetes, substance abuse, and use of DAA regimens without ribavirin were significant predictors of achieving SVR12. Patients with fewer comorbidities, better liver health, and lower HCV viral loads at baseline were more likely to achieve treatment success. Our results were consistent with other real-world studies, supporting the use of HCV therapy in HIV/HCV coinfected patients.
Introduction

It is estimated that 2.27 to 2.75 million people around the world have hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection.[1–3] In the United States (US), of the people living with HIV (PLWH), about 25% are estimated to have HCV infection, which consequently triples the risk for liver disease, liver failure, and liver related death. [4] Nearly 75% to 82% of PLWH who inject drugs are also infected with HCV.[2,4,5] Prior to potent combination antiretroviral therapy (ART), early studies suggested that progression to fibrosis is accelerated in patients with HIV/HCV coinfection. Factors affecting disease progression in this population include increased alcohol use, older age, longer duration of HCV infection, and immunosuppression (CD4 < 200 cells/mm³). More recent data, however, show a similar course of progression in HIV positive patients primarily due to sufficient immune reconstitution in the modern ART era.[6–9] Notwithstanding, HIV/HCV coinfection has been associated with increased risk of death in large cohort studies compared to HIV monoinfection.[9–12] Advanced liver disease accounted for 13% of all deaths among PLWH prior to treatment with direct-acting antivirals (DAAs), and in the US chronic HCV infection has been shown to be the leading cause of liver disease and related mortality in coinfected individuals.[13–17]

In the past, persons with HIV/HCV coinfection achieved lower rates of sustained virologic response (SVR) after use of interferon and ribavirin HCV treatment compared with those with HCV mono-infection.[5] In addition to poor efficacy, older HCV treatment regimens were associated with many adverse effects such as depression, anemia, flu-like symptoms, and were often contraindicated due to additional comorbidities within the PLWH.[18–20] With the development of interferon-free DAA therapies, the treatment platform for PLWH has been revolutionized and efficacy in patients with HIV/HCV coinfection has improved. There are recent published clinical trials that reported high rates of SVR (>90%) with DAA therapy in patients with HIV/HCV coinfection.[21] However, the rigid inclusion criteria in these clinical trials may not be an accurate representation of patients with HIV/HCV coinfection in clinical care. [22–27] Many co-infected patients, especially those in urban clinics, struggle with psychosocial issues such as drug and alcohol abuse, unstable housing, and mental health disparities. Access to medications due to individual state restrictions as well as drug interactions with antiretrovirals remain a challenge in this patient population. Substance abuse remains a common restriction on many state Medicaid plans.[20, 28–31]

HCV treatment can be complicated with the number of drug-drug interactions associated with antiretroviral therapies; however, the Department of Health and Human Services (DHHS) recommends first-line ART regimens with minimal drug interactions and that are compatible with most DAA therapies. There has been concern that SVR results obtained in clinical trials may not be generalizable due to the selection of patients or stringent inclusion criteria; however a number of real-world studies in the US have been completed and reported high rates of both adherence and SVR in the HIV/HCV coinfected population.[32–38] Some of these studies have evaluated efficacy of specific DAA therapies in one clinic/hospital setting with small patient sample sizes (range 30–109 patients) using US data.[32,33,35,37,38] One study by Del Bello et al evaluated predictors of treatment failure, which included fibrosis-4 (FIB-4) score ≥3.25, low AST levels, and use of simeprevir/sofosbuvir/ribavirin (SMV/SOF/ RBV); however, the sample consisted of 89 patients with genotype 1 treated in a hospital setting in New York, USA.[34] These studies have added valuable real-world evidence by reporting high SVR rates comparable to those seen in clinical trials, but had some limitations such as small patient numbers, use of data prior to 2018, and single sites and thus are not easily generalizable to other institutions and geographic regions.
There are limited data from multi-site HIV clinics across the US, including patients with multiple HCV genotypes and all DAA therapies, and identifying factors associated with treatment response. Our objective for this analysis was to evaluate the SVR rates assessed at 12 weeks after completion of DAA therapy and to identify predictors of SVR12 achievement among patients with HIV/HCV coinfection using a multi-site HIV database.

Materials and methods

Study design and data
This was an observational retrospective cohort study using real-world data with linked electronic medical records (EMR) and pharmacy dispense data from a proprietary longitudinal database established by Trio Health. The database contains records of over 38,000 HIV patients from 50 US states and Puerto Rico. The data generated through the EMR are available for research purposes and include information on patient clinical and demographic characteristics, prescriptions and dispenses, coded diagnoses, and laboratory test results collected at 11 large HIV-treating US clinics since 2014. This study was approved as an Institutional Review Board (IRB) exemption under category 45 CFR 46 that waived the requirement for informed consent, since this was a retrospective database study without direct patient contact using de-identified data.

Study population
Patients coinfected with HCV/HIV, aged ≥18 years old, who initiated DAA +/- ribavirin therapies (HCV regimen) from January 1, 2014 to March 31, 2017 were identified. The index date was defined as the date of HCV regimen initiation using pharmacy dispensing records. Patients were followed until their SVR was assessed at 12 weeks after completion of their HCV regimen. Patients were further categorized as achieving SVR12 and not achieving SVR12. Baseline characteristics included, age, gender, ethnicity, geographic region, body mass index (BMI), fibrosis burden (FIB-4 score), transplant status, and comorbidities (cancer, cirrhosis, depression, diabetes, hepatitis B infection, heart disorders [cardiovascular disease, coronary artery disease, aortic aneurysm], chronic kidney disease, substance abuse). Collected laboratory values included HCV genotype, initial viral load, alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels, total bilirubin levels, absolute CD4+ T-cell counts (CD4 count), and HIV viral load.

Study outcomes
The outcomes of the study were to evaluate the rates of SVR12 and to identify factors associated with SVR12 among HCV/HIV coinfected patients. SVR12 was defined as an undetectable plasma HCV RNA at 12 weeks after completion of HCV regimen.

Statistical analysis
Unadjusted descriptive statistics summarized patient characteristics of the two study cohorts (achieving SVR12 versus not achieving SVR12). Differences between these patient groups were tested using Student’s t test or Mann-Whitney test for continuous variables and chi squared statistic or Fisher’s exact tests for categorical variables. A multivariable logistic regression model was generated with SVR12 success as the dependent variable. Some of the potential risk factors for the model included demographic information (age, gender, ethnicity, geographic region); indices of liver disease severity (cirrhosis, FIB-4 score>3.25, and liver transplant); HCV genotype; laboratory results such as HCV viral load, absolute CD4 cell count,
ALT, AST levels; comorbidities (depression, diabetes, chronic kidney disease, substance abuse, etc.). A backwards stepwise selection process was used to include factors with the significance level of $P \leq 0.2$ for the final model. Odds ratio (OR) and 95% confidence intervals (95% CI) for predictors of achieving SVR from the logistic regression model were reported. All analyses were conducted using SAS 9.4 software (SAS Institute, Cary, NC). A two-sided $P$ value $<0.05$ was considered statistically significant.

**Results**

A total of 450 HCV/HIV coinfected patients were identified on HCV regimens from January 1, 2014 to March 31, 2017. Of them, 6 patients died during the follow-up period, 4 discontinued treatment, and 8 were lost to follow-up. The final study cohort included 432 patients who completed DAA therapy and were evaluated for SVR12 (Fig 1).

Of the patients who completed therapy and were assessed for SVR12, 404 patients (94%) achieved SVR12 and 28 patients (6%) experienced virologic failure.

**Patient characteristics**

The baseline clinical and demographic patient characteristics are described in Table 1. Patients who achieved SVR12 (SVR12 group) were older than those who did not achieve SVR12 (non-SVR12 group) with mean age 55.3 years vs 51.7 years as shown in Table 1.

There were no statistically significant differences between the two study groups by gender, ethnicity, insurance type, geographic region, BMI categories, or HCV genotype. Most of the patients (>70%) had genotype 1 infection (GT1A, GT1B, and GT1X) within both groups. Compared to the SVR12 group, the non-SVR12 group had significantly higher proportion of patients with CD4 counts <200 cells/mm$^3$, HCV viral load >800K IU/ML, and FIB-4 score >3.25 as well as higher mean ALT, AST, and total bilirubin. The SVR12 group had fewer comorbidities than the non-SVR12 group, with lower rates of cancer (6.9% vs 14.3%, $p = 0.016$), cirrhosis (22.0% vs 40.7%, $p = 0.026$), depression (33.1% vs 50.0%, $p = 0.039$), diabetes (13.1% vs 21.4%, $p = 0.022$), hepatitis B infection (2.2 vs 7.1%, $p = 0.031$), chronic kidney disease (11.9 vs 17.9%, $p = 0.035$), substance abuse (34.9% vs 57.1%, $p = 0.018$), and tobacco use (45.3% vs 57.1%, $p = 0.022$).

**HCV regimens**

Patients in the SVR12 group were mostly on DAA therapies without concomitant ribavirin (RBV) therapy compared to the non-SVR12 group (85.4% [n = 345] vs 60.7% [n = 17]). The majority of SVR12 patients (67.3% [n = 272]) received ledipasvir-sofosbuvir (LDV+SOF) compared to 46.4% (n = 13) of the patients in the non-SVR12 group. Patients in the non-SVR12 group were more likely to be on DAA with concomitant RBV therapy (39.3% [n = 11]) compared to SVR12 group (14.6% [n = 59]). Patients who did not receive ribavirin therapy achieved treatment success 95.3% of the time, while those who received ribavirin achieved SVR12 84.3% of the time. Table 2 lists treatment success rates by regimen.

**Predictive factors associated with SVR12 success**

In the final multivariable logistic regression model, several factors were associated with achieving SVR12 Table 3.

Older patients were more likely to achieve SVR12 (OR 1.14, 95 CI: 1.03–1.27, $p = 0.011$). Patients with baseline depression (OR 0.82, 95 CI: 0.02–0.96, $p = 0.040$), diabetes (OR 0.68, 95 CI: 0.13–0.94, $p = 0.028$), substance abuse (OR 0.48, 95 CI: 0.07–0.97, $p = 0.039$), and on
Patients with HIV/HCV coinfection initiated on DAA therapy during January 1, 2014 - March 31, 2017 (identification period) N=450

Exclude:
- Patients expired during follow up (n=6)
- Patients discontinued treatment (n=4)

Patients with HIV/HCV coinfection completed DAA therapy N=440

Exclude:
- Patients lost to follow up N=8

SVR12 assessed after completion of DAA therapy N=432

SVR12 Achieved N=404 (94%)
SVR12 Not Achieved N=28 (6%)

Fig 1. Patient cohort flow diagram. DAA = direct acting antiviral; HIV = human immunodeficiency virus; HCV = hepatitis C virus; SVR12 = sustained virologic response assessed 12 weeks after completion of DAA therapy.

https://doi.org/10.1371/journal.pone.0228847.g001
Table 1. Baseline clinical and demographic characteristics.

|                              | Total Population  | SVR12 N = 404 | No SVR12 N = 28 | P-value* |
|------------------------------|-------------------|---------------|----------------|----------|
| **Age (years), mean ± SD**   | 55.7±9.7          | 55.3±9.2      | 51.7±9.4       | 0.039    |
| **Gender, n (%)**            |                   |               |                | 0.561    |
| Male                         | 335 (77.5%)       | 312 (77.2%)   | 23 (82.1%)     |          |
| Female                       | 96 (22.2%)        | 91 (22.5%)    | 5 (17.8%)      |          |
| Unknown                      | 1 (0.2%)          | 1 (0.3%)      | 0 (0.0%)       |          |
| **Ethnicity, n (%)**         |                   |               |                | 0.101    |
| Black                        | 236 (54.6%)       | 225 (55.7%)   | 11 (39.3%)     |          |
| White                        | 101 (23.4%)       | 90 (22.3%)    | 11 (39.3%)     |          |
| Hispanic                     | 73 (16.9%)        | 67 (16.6%)    | 6 (21.4%)      |          |
| Unknown                      | 22 (5.1%)         | 22 (5.5%)     | 0 (0.0%)       |          |
| **Insurance Type, n (%)**    |                   |               |                | 0.587    |
| Commercial                   | 54 (12.5%)        | 51 (12.6%)    | 3 (10.7%)      |          |
| Medicaid                     | 148 (34.3%)       | 136 (33.7%)   | 12 (42.9%)     |          |
| Medicare                     | 81 (18.7%)        | 78 (19.3%)    | 3 (10.7%)      |          |
| Self-pay                     | 13 (3.0%)         | 13 (3.2%)     | 0 (0.0%)       |          |
| Other or unknown             | 136 (31.4%)       | 126 (31.2%)   | 10 (35.7%)     |          |
| **BMI, n (%)**               |                   |               |                | 0.893    |
| Underweight: <18.5           | 8 (1.8%)          | 8 (2.4%)      | 0 (0.0%)       |          |
| Normal weight: 18.5 to 24.9  | 168 (28.9%)       | 156 (46.0%)   | 12 (48.0%)     |          |
| Overweight: > 25.0 to 29.9   | 103 (23.8%)       | 96 (26.3%)    | 7 (28.0%)      |          |
| Obese: ≥30                   | 85 (19.7%)        | 79 (23.3%)    | 6 (24.0%)      |          |
| Unknown                      | 68 (15.7%)        | 65 (16.1%)    | 3 (10.7%)      |          |
| **Genotype, n (%)**          |                   |               |                | 0.713    |
| Not genotyped                | 2 (0.5%)          | 2 (0.5%)      | 0 (0.0%)       |          |
| Genotyped                    |                   |               |                |          |
| GT1A                         | 275 (63.7%)       | 256 (63.4%)   | 19 (67.9%)     | 0.936    |
| GT1B                         | 92 (21.2%)        | 87 (21.5%)    | 5 (17.9%)      |          |
| GT1X                         | 7 (1.6%)          | 6 (1.5%)      | 1 (3.6%)       |          |
| GT2                          | 25 (5.8%)         | 23 (5.7%)     | 2 (7.1%)       |          |
| GT3                          | 27 (6.3%)         | 26 (6.4%)     | 1 (3.6%)       |          |
| GT4                          | 4 (0.9%)          | 4 (1.0%)      | 0 (0.0%)       |          |
| **Baseline Labs**            |                   |               |                |          |
| CD4 count, n (%)             | 325 (75.2%)       | 303 (75.0%)   | 22 (78.6%)     | 0.826    |
| CD4 count <200 cells/ mm³, n (%) | 27 (6.3%)    | 24 (7.9%)   | 3 (13.6%)     | 0.035    |
| Initial HCV VL, n (%)        | 358 (82.9%)       | 334 (82.7%)   | 24 (85.7%)     | 0.128    |
| HCV VL <800K IU/ML           | 92 (21.3%)        | 90 (27.0%)    | 2 (3.8%)       | 0.021    |
| HCV VL 800K-6MM IU/ML        | 210 (48.6%)       | 193 (57.8%)   | 17 (70.8%)     |          |
| HCV VL >6MM IU/ML            | 56 (12.9%)        | 51 (15.3%)    | 5 (20.8%)      |          |
| HIV VL, n (%)                | 357 (82.6%)       | 334 (82.7%)   | 23 (82.1%)     | 0.701    |
| HIV VL <200 copies/ML, n (%) | 336 (77.8%)       | 315 (94.3%)   | 21 (91.3%)     | 0.553    |
| ALT*, n (%)                  | 349 (80.8%)       | 324 (80.2%)   | 25 (89.2%)     | 0.611    |

(Continued)
ribavirin therapy (OR 0.13, CI: 0.03–0.60, p = 0.009) were less likely to achieve SVR12. Baseline HCV viral load <800K IU/ML was associated with 13 times greater likelihood of achieving SVR12 versus having an HCV viral load between 800K to 6MM IU/ML (OR 13.77, CI: 5.37–18.82, p = 0.026). Patients with FIB-4 score <1.45 were 5 times more likely to achieve SVR12 (OR 5.18, 95% CI: 1.12–8.28, p = 0.008) compared to those with FIB-4 1.45 to ≤3.25.

### Table 1. (Continued)

| Comorbidities, n (%) | Total Population N = 432 | SVR12 N = 404 | No SVR12 N = 28 | P-value$^a$ |
|---------------------|--------------------------|----------------|-----------------|-------------|
| Asthma              | 62 (14.4%)               | 59 (14.6%)     | 3 (10.7%)       | 0.570       |
| Cancer              | 32 (7.4%)                | 28 (6.9%)      | 4 (14.3%)       | 0.016       |
| Cirrhosis           | 100 (23.1%)              | 89 (22.0%)     | 11 (40.7%)      | 0.026       |
| Depression          | 148 (34.3%)              | 134 (33.1%)    | 14 (50.0%)      | 0.039       |
| Diabetes            | 59 (13.6%)               | 53 (13.1%)     | 6 (21.4%)       | 0.022       |
| Heart Disorders$^h$ | 68 (15.7%)               | 67 (16.6%)     | 1 (3.6%)        | 0.016       |
| Hepatitis B Infection | 11 (2.5%)            | 9 (2.2%)       | 2 (7.1%)        | 0.031       |
| Hypertension        | 186 (43.1%)              | 173 (42.8%)    | 13 (46.4%)      | 0.709       |
| Hyperlipidemia      | 76 (17.6%)               | 72 (17.8%)     | 4 (14.3%)       | 0.635       |
| Chronic kidney disease | 53 (12.2%)              | 48 (11.9%)     | 5 (17.9%)       | 0.035       |
| Liver transplant recipient | 1 (0.2%)        | 0 (0.0%)       | 1 (3.6%)        | 0.065       |
| Psychiatric Disorders | 87 (20.1%)            | 81 (20.1%)     | 6 (21.4%)       | 0.860       |
| Substance abuse     | 157 (36.3%)              | 141 (34.9%)    | 16 (57.1%)      | 0.018       |
| Tobacco use         | 199 (46.1%)              | 183 (45.3%)    | 16 (57.1%)      | 0.022       |
| DAA Therapies       |                          |                |                 | 0.001       |
| + RBVi, n (%)       | 70 (16.2%)               | 59 (14.6%)     | 11 (39.3%)      |             |
| - RBV, n (%)        | 362 (83.8%)              | 345 (85.4%)    | 17 (60.7%)      |             |

$^a$ P-value < 0.05 was considered statistically significant.

$^b$ BMI = body mass index.

$^c$ GT = genotype.

$^d$ VL = viral load.

$^e$ ALT = alanine aminotransferase.

$^f$ AST = aspartate aminotransferase.

$^g$ FIB-4 = fibrosis-4 score for liver.

$^h$ Heart disorders = cardiovascular disease, coronary artery disease, aortic aneurysm.

$^i$ RBV = ribavirin.

https://doi.org/10.1371/journal.pone.0228847.t001
Discussion

To our knowledge, this is one of the largest US cohort studies of patients with HIV/HCV coinfection who initiated DAA therapies in a real-world setting. In this analysis, we observed SVR12 rates of 94%, consistent with prior real-world studies showing >90% SVR rates. \[32,35,38\] Current guidelines\[39\] recommend that patients with HIV/HCV coinfection be treated using the approach followed for non-HIV infected patients, because efficacy of current DAA regimens does not differ between HCV-mono-infected and coinfected patients, while PLWH represent an especially vulnerable population. In HIV-infected men having sex with men (MSM) HCV transmission continues to rise; therefore, HCV elimination efforts directed toward this population will be important to decrease the HCV reservoir to prevent further transmission. \[40–42\] Treatment of HCV as prevention in this high risk population is critical to decrease the overall HCV incidence in PLWH, particularly with the expansion of the HIV U = U (undetectable = untransmissible) message in clinics across the US.\[43,44\] Although an empowering message for PLWH, the U = U message has the potential to increase the incidence of acute HCV in patients engaging in condomless sex.\[45,46\]

Possible barriers to a successful HCV response in PLWH include access to medical care, timely diagnosis of HIV/HCV and initiation of DAA therapy, costs associated with therapy, underinsured status, longer time needed for screening HIV/HCV and time required for counseling.\[5,47\] Achieving SVR12 has also been shown to affect quality of life (QoL) in

Table 2. HCV therapies and treatment success.

| HCV Therapies   | Total Population N = 432 | SVR12 N = 404 | No SVR12 N = 28 |
|-----------------|--------------------------|---------------|-----------------|
| DAA + RBV\[a\] | 70 (16.2%)               | 59 (84.3%)    | 11 (15.7%)      |
| SOF\[b\] + RBV | 39 (9.0%)                | 32 (82.1%)    | 7 (17.9%)       |
| PROD\[c\] + RBV | 13 (3.0%)                | 10 (76.9%)    | 3 (23.1%)       |
| SOF + PEG\[d\] + RBV | 6 (1.4%) | 6 (100.0%)    | 0 (0.0%)        |
| LDV\[e\] + SOF + RBV | 5 (1.2%) | 5 (100.0%)    | 0 (0.0%)        |
| SMV\[f\] + SOF + RBV | 4 (0.9%) | 3 (75.0%)    | 1 (25.0%)       |
| SOF-VEL\[g\] + RBV | 2 (0.5%) | 2 (100.0%)    | 0 (0.0%)        |
| DCV\[h\] + SOF + RBV | 1 (0.2%) | 1 (100.0%)    | 0 (0.0%)        |
| DAA–RBV        | 362 (83.8%)              | 345 (95.3%)   | 17 (4.7%)       |
| LDV-SOF        | 285 (66.0%)              | 272 (95.4%)   | 13 (4.6%)       |
| SMV + SOF      | 29 (6.7%)                | 27 (93.1%)    | 2 (6.9%)        |
| EBR-GZR\[i\]  | 17 (3.9%)                | 16 (94.1%)    | 1 (5.9%)        |
| DCV + SOF      | 15 (3.5%)                | 15 (100.0%)   | 0 (0.0%)        |
| SOF + VEL      | 11 (2.5%)                | 10 (90.9%)    | 1 (9.1%)        |
| PROD           | 5 (1.2%)                 | 5 (100.0%)    | 0 (0.0%)        |

\[a\] RBV = ribavirin.  
\[b\] SOF = sofosbuvir.  
\[c\] PROD = paritaprevir/ritonavir-ombitasvir and dasabuvir.  
\[d\] PEG = peginterferon.  
\[e\] LDV = ledipasvir.  
\[f\] SMV = simeprevir.  
\[g\] VEL = velpatasvir.  
\[h\] DCV = daclatasvir.  
\[i\] EBR-GZR = elbasvir-grazoprevir.

https://doi.org/10.1371/journal.pone.0228847.t002
patients with HIV/HCV coinfection. Prior to DAA therapy availability, QoL reported by patients with HIV/HCV coinfection was significantly lower than in HIV mono-infected patients.[16,48] However, after completion of DAA therapy, QoL scores were comparable between the two study groups, and DAA therapy demonstrated improvement in general health and emotional well-being of patients with HIV/HCV coinfection.[48] Overall, the advent of DAA therapy has had a positive impact on this population.

High SVR rates achieved with DAA therapy and the small number of patients included in the registration trials have made it difficult to identify factors associated with treatment failure in both monoinfected and coinfected patients.[49] Therefore, we evaluated predictors of treatment success. Based on baseline characteristics, patients with SVR12 had lower rates of comorbidities, lower HCV viral loads and ALT, AST levels, and FIB-4 score compared to the non-SVR group. The descriptive findings were consistent with the multivariable model, where patients with older age, less fibrotic liver (FIB-4 score $< 1.45$) and lower levels of HCV initial viral load ($< 800K$ IU/ML) were more likely to achieve treatment success (SVR12). Factors such as depression, diabetes, substance abuse, HCV viral load $> 6$MM IU/ML, FIB-4 score $> 3.25$, CD4 count $< 200$ cells/mm$^3$, and DAA plus ribavirin therapy were independently associated with not achieving SVR12. However, these findings should not be interpreted as lack of DAA efficacy in these groups as SVR12 rates were still high in patients with CD4 $< 200$ cells/mm$^3$ (88.8% [n = 27]), depression (90.5% [n = 148]), and substance abuse (89.8% [n = 157]).

Prior studies supported our findings as related to factors associated with not achieving SVR12. Berenguer et al found male sex, CD4 count $< 200$ cells/mm$^3$, HCV RNA viral load $\geq 800$K IU/mL, compensated cirrhosis, and the use of sofosbuvir plus ribavirin were associated

Table 3. Factors associated with SVR12 achievement.

| Patient Characteristics | Odds Ratio (95% CI) | P-value$^a$ |
|-------------------------|---------------------|-------------|
| Age                     | 1.14 (1.03–1.27)    | 0.011       |
| Cirrhosis               | 0.34 (0.09–1.34)    | 0.126       |
| Depression              | 0.82 (0.02–0.96)    | 0.040       |
| Diabetes                | 0.68 (0.13–0.94)    | 0.028       |
| Substance abuse         | 0.48 (0.07–0.97)    | 0.039       |
| **Baseline Initial Viral Load** |                     |            |
| HCV VL$^b < 800K$ IU/ML | 13.77 (5.37–18.82)  | 0.026       |
| HCV VL 800K to 6MM IU/ML| 1.00                | -           |
| HCV VL >6MM IU/ML       | 0.57 (0.16–2.08)    | 0.398       |
| **Baseline FIB-4$^c$**  |                     |            |
| FIB-4 $< 1.45$          | 5.18 (1.12–8.28)    | 0.0008      |
| FIB-4 1.45 to $\leq 3.25$| 1.00                | -           |
| FIB-4 $> 3.25$          | 0.54 (0.16–1.84)    | 0.327       |
| **Baseline CD4 count**  |                     |            |
| $\geq 200$ cells/mm$^3$ | 1.00                | -           |
| $< 200$ cells/mm$^3$    | 0.42 (0.11–1.92)    | 0.265       |
| **DAA Therapies**       |                     |            |
| HCV regimen—RBV$^d$     | 1.00                | -           |
| HCV regimen + RBV       | 0.13 (0.03–0.60)    | 0.009       |

$^a$ C-statistic (model fit) = 0.899; p-value $< 0.05$ was considered statistically significant.

$^b$ VL = viral load.

$^c$ FIB-4 = fibrosis-4 score for liver.

$^d$ RBV = ribavirin.

https://doi.org/10.1371/journal.pone.0228847.1003
with treatment failure based on the analysis of patients in Madrid, Spain.[49] Del Bello et al found that patients receiving simeprevir/sofosbuvir/ribavirin therapy were more likely to have treatment failure.[34] Tapper et al found that presence of cirrhosis, prior treatment experience, treatment at an academic center, and treatment outside of the FDA recommendations were each associated with lower odds of achieving SVR.[50]

In the few patients who experienced treatment failure, active drug and alcohol use and depression were the greatest predictors of not achieving SVR. Based on prior studies, drug use within 6 months of initiating HCV therapy is not associated with decline in response to treatment; however, more frequent drug use correlates with decreased efficacy of treatment.[51–55] Social functioning, including unstable housing, transportation difficulties, stigmatization, and clinic attendance are better indicators of treatment outcome, independently associated with SVR after adjusting for drug use.[56] International guidelines support prioritizing persons at risk for transmitting HCV, including active injection drug users, to reduce the duration that the person is infectious.[57] Colocation of HIV care, HCV testing and treatment, medically assisted treatment for illicit drug use, and mental health services, as offered in the majority of the clinical settings in our study, can increase success rates on HCV therapy in this population.[58,59]

Limitations of this multicenter retrospective study include lack of uniformity of staging modalities other than FIB-4 calculations to determine severity of fibrosis, which may have generated variability in center-specific HCV treatment decisions. In addition, many coinfected patients with active drug or alcohol abuse within these HIV centers may have been excluded from DAA eligibility due to strict individual state Medicaid restrictions denying access to these medications, which may limit the generalizability of these results to these subpopulations.[60] In the Canadian Coinfection Cohort (CCC), a representative HIV/HCV population in an industrialized country was used to evaluate the percentage of current cohort participants who would be eligible to participate in all oral DAA clinical trials. Exclusivity to specific antiretroviral therapies as well as illicit drug use excluded greater than 50% of the HIV co-infected population from receiving HCV treatment.[61] Individual state level Medicaid restrictions in several jurisdictions in the US also require rigid criteria as to who has access to DAA therapy, potentially limiting these curative therapies among PLWH.[30]

Additionally, due to the heterogeneity of HIV regimens in the sample, they were not included in the model. Lastly, the database platform does not record DAA adherence patterns, a behavioral factor central to successful DAA treatment. However, shorter courses of treatment and the inclusion of the dispensing records in this database provides some reassurance that the medications were taken properly.

Conclusions
Currently, there are limited real-world data on HCV treatment outcomes for patients with HIV/HCV coinfection. This large, real-world, multi-site, US study evaluating rates of SVR12 achievement and factors associated with treatment success significantly contributes to evidence in the coinfected population. In this analysis of patients with HIV/HCV coinfection, we found DAA therapies to be effective, with 94% of the patients achieving SVR12, consistent with rates seen in monoinfected HCV patients. Baseline variables, including older age, HCV viral load <800K IU/ML, FIB-4 score <1.45, absence of depression, diabetes, substance abuse, and use of DAA regimens without ribavirin were significant predictors of achieving SVR12. However, even in patients with characteristics negatively associated with achieving SVR12, success rates were high compared to success rates prior to DAA regimen availability. Patients with fewer comorbidities, better liver health, and lower HCV viral loads at baseline were more
likely to achieve treatment success. Our results were consistent with other real-world studies, supporting the use of HCV therapy in HIV/HCV coinfected patients.

**Acknowledgments**

The authors thank Matthew Budday (Trio Health) for assisting with data collection on this project and Nazia Rashid (Trio Health) for medical writing support.

**Author Contributions**

**Conceptualization:** Dushyantha T. Jayaweera, Keri N. Althoff, Joseph J. Eron, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax, Jason Gillman, Karam Mounzer, Richard A. Elion, Gregory D. Huhn.

**Data curation:** Janna Radtchenko, Richard A. Elion.

**Formal analysis:** Janna Radtchenko.

**Investigation:** Sonia Vibhakar Patel, Dushyantha T. Jayaweera, Anthony Mills, Steven Santiago, Jason Gillman, Karam Mounzer, Gregory D. Huhn.

**Methodology:** Dushyantha T. Jayaweera, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax, Jason Gillman, Karam Mounzer, Richard A. Elion, Gregory D. Huhn.

**Project administration:** Janna Radtchenko, Richard A. Elion, Gregory D. Huhn.

**Supervision:** Keri N. Althoff, Joseph J. Eron, Graeme Moyle, Paul E. Sax, Richard A. Elion, Gregory D. Huhn.

**Validation:** Sonia Vibhakar Patel, Janna Radtchenko, Richard A. Elion.

**Visualization:** Janna Radtchenko.

**Writing – original draft:** Sonia Vibhakar Patel.

**Writing – review & editing:** Sonia Vibhakar Patel, Janna Radtchenko, Richard A. Elion, Gregory D. Huhn.

**References**

1. Abutaleb A, Sherman K. A changing paradigm: management and treatment of the HCV/HIV-coinfected patient. Hepatology International. 2018; 12: 500–509. https://doi.org/10.1007/s12072-018-9896-4 PMID: 30238230

2. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016; 16(7): 797–808 https://doi.org/10.1016/S1473-3099(15)00485-5 PMID: 26922272

3. World Health Organization. HIV and hepatitis coinfections. https://www.who.int/hiv/topics/hepatitis/en/ Cited December 20 2018.

4. Centers for Disease Control and Prevention. Epidemiology and Prevention of HIV and Viral Hepatitis Co-infections. https://www.cdc.gov/hiv/pdf/library/factsheets/hiv-viral-hepatitis.pdf. Cited December 20 2018.

5. Meissner EG. Update in HIV/HCV Co-Infection in the Direct Acting Antiviral Era Curr Opin Gastroenterol. 2017; 33(3): 120–127. https://doi.org/10.1097/MOG.0000000000000347 PMID: 28234770

6. Lo Re V 3rd, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, et al. Hepatic decompensation in anti-retroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014; 160: 369–379. https://doi.org/10.7326/M13-1829 PMID: 24723077
7. Konerman MA, Mehta SH, Sutcliffe CG, Vu T, Higgins Y, Torbenson MS, et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology. 2014; 59(3): 767–75. https://doi.org/10.1002/hep.26741 PMID: 24436062

8. Sterling RK, Wegelin JA, Smith PG, Stravitz RT, Luketic VA, Fuchs M, et al. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples. Clin Gastroenterol. 2010; 8(12):1070–1076. https://doi.org/10.1016/j.cgh.2010.08.004 PMID: 20728569

9. Van der Helm J, Geskus R, Sabin C, Meyer L, del Amo J, Chêneet G, et al. Effect of HCV Infection on Cause-Specific Mortality After HIV Seroreversion, Before and After 1997. Gastroenterology. 2013; 144(4): 751–760. https://doi.org/10.1053/j.gastro.2012.12.026 PMID: 23266560

10. Thornton AC, Jose S, Bhegani S, Chadwick D, Dunn D, Gilson R, et al. Hepatitis B, Hepatitis C, and mortality among HIV-positive individuals. AIDS. 2017; 31(18): 2525–2532. https://doi.org/10.1097/QAD.0000000000001646 PMID: 28926400

11. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med. 2006; 166: 1632–1641. https://doi.org/10.1001/archinte.166.15.1632 PMID: 16908797

12. Chen TY, Ding EL, Seage-III GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009; 49(10): 1605–1615. https://doi.org/10.1086/644771 PMID: 19842982

13. Brau N, Salvatore M, Rios-Bedoya CF, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo JF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006; 44(1): 47–55. https://doi.org/10.1016/j.jhep.2005.07.006 PMID: 16182404

14. Klein MB, Atthoff KN, Jing Y, Lau B, Kitahata M, Lo Re V III, et al. Risk of end-stage liver disease in HIV-hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 2016; 63(9): 1160–1167. https://doi.org/10.1093/cid/ciw531 PMID: 27506682

15. Mena A, Meijide H, Rodriguez-Osorio I, Castro A, Poveda E, Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV. HIV Med. 2017; 18(9): 685–689. https://doi.org/10.1111/hiv.12502 PMID: 28230318

16. Sikavi C, Chen P, Lee A, Saab EG, Choi G, Saab S, et al. Hepatitis C and Human Immunodeficiency Virus coinfection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult-to-Treat Population. Hepatology 2018; 67 (3): 847–857. https://doi.org/10.1002/hep.29642 PMID: 29108121

17. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011: a multicohort collaboration. Lancet 2014; 384(9939): 241–248. https://doi.org/10.1016/S0140-6736(14)60604-8 PMID: 25042294

18. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Shermanet KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004; 351(5): 451–459. https://doi.org/10.1056/NEJMoa032653 PMID: 15282362

19. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of anti-viral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006 Nov 28; 20(18): 2361–2369. https://doi.org/10.1097/QAD.0b013e32801086da PMID: 17117023

20. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu. Rev. Med. 2008; 59: 473–485. https://doi.org/10.1146/annurev.med.59.081906.081110 PMID: 18186707

21. Wyles DL, Sulkowski MS, Dieterich D. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis. 2016; 63(Suppl 1): S3–S11. Recent comprehensive review of clinical trials design, results, and outcomes, as well as discussion of clinical management of HIV/HCV co-infected persons.

22. Bhattacharya D, Belperio PS, Shahoumian TA, Loomis TP, Goetz MB, Mole LA, et al. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice. Clin Infect Dis. 2017; 64(12): 1711–1720. https://doi.org/10.1097/QAD.0b013e32861086da PMID: 17117023

23. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373(8): 705–713. https://doi.org/10.1056/NEJMoa1501315 PMID: 26196665

24. Sulkowski MS, Eron JJ, Wyles DL, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015; 313(12): 1223–1231. https://doi.org/10.1001/jama.2015.1328 PMID: 25706092

25. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HIV in patients coinfected with HCV-1. N Engl J Med. 2015; 373(8): 714–725. https://doi.org/10.1056/NEJMoa1503153 PMID: 26196502
26. Wyles D, Bräu N, Kottlari S, Daar ES, Ruane P, Workowski K, et al. Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: An Open-Label, Phase 3 Study. Clin Infect Dis. 2017; 65(1): 6–12. https://doi.org/10.1093/cid/cix260 PMID: 28369210

27. Sulikowski MS, Nagge S, Lalezari J, Fessel WJ, Mouzner K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014; 312(4): 353–361. https://doi.org/10.1001/jama.2014.7734 PMID: 25038354

28. Oramasionwu CU, Moore HN, Toliver JC. Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review. AIDS Patient Care STDS. 2014; 28(5): 228–39. https://doi.org/10.1089/apc.2014.0033 PMID: 24738846

29. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. http://aidsinfo.nih.gov Cited December 7 2018.

30. National Hepatitis Roundtable. Hepatitis C: State of Medicaid Access. https://stateofhepc.org/wp-content/uploads/2017/10/State-of-Access-Infographic.pdf Cited December 7 2018.

31. Barua S, Greenwald R, Grebely J., Dore GJ, Swan T, Taylor LE, et al. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163: 215–223. https://doi.org/10.7326/M15-0406 PMID: 26120969

32. Hawkins C, Grant J, Ammerman LR, Palella F, McLaughlin M, Green R, et al. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. J Antimicrob Chemother. 2016; 71: 2642–2645. https://doi.org/10.1093/jac/dkw203 PMID: 27330060

33. Cachay ER, Wyles D, Hill L, Ballard C, Torriani F, Colwell B, et al. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients with Ongoing Barriers to Care. Open Forum Infect Dis. 2015; 2(4): ofv168. https://doi.org/10.1093/ofid/ofv168 PMID: 26697509

34. Del Bello D, Cha A, Sorbera M, Bichoupan K, Levine C, Doyle E, et al. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. Clin Infect Dis. 2016; 62: 1497–1504. https://doi.org/10.1093/cid/ciw119 PMID: 26936665

35. Rowan SE, Rogers M, Bayer J, Smith L, Gardner EM, Johnson S, et al. Treatment of Hepatitis C Virus (HCV)-infected and HCV/HIV-coinfected patients with Cirrhosis Are Efficient and Safe: Real-life Results from the Prospective ANRS CO13-HEPAVH Cohort. Clin Infect Dis. 2016; 63: 673–770. https://doi.org/10.1093/cid/ci379 PMID: 27317796

36. Townsend K, Petersen T, Gordon LA, Kohli A, Nelson A, Seamon C, et al. Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. AIDS. 2016; 30: 261–266. https://doi.org/10.1097/QAD.000000000000093 PMID: 26691547

37. Witt MD, Seaberg EC, Donlay A, Young S, Badri S, Rinaldo CR, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984–2011. Clin Infect Dis. 2013; 57: 77–84. https://doi.org/10.1093/cid/cit197 PMID: 23532480

38. CDC. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men—New York City, 2005–2010. MMWR. Morbidity and mortality weekly report. 2011; 60(28): 945–950. PMID: 22177594

39. Braun D, Hampel B, Nguyen H, Flepp M, Stoeckle M, Bégueline C, et al. A Treatment as Prevention Trial to Eliminate HCV in HIV+ MSM: The SWISS HCVREE Trial. Conference on Retroviruses and Opportunistic Infections (CROI) 2018 abstract 81LB. http://www.croiconference.org/sessions/treatment-prevention-trial-eliminate-hcv-hiv-msm-swiss-hcvree-trial Cited December 7 2018.

40. Braun D, Hampel B, Nguyen H, Flepp M, Stoeckle M, Bégueline C, et al. A Treatment as Prevention Trial to Eliminate HCV in HIV+ MSM: The SWISS HCVREE Trial. Conference on Retroviruses and Opportunistic Infections (CROI) 2018 abstract 81LB. http://www.croiconference.org/sessions/treatment-prevention-trial-eliminate-hcv-hiv-msm-swiss-hcvree-trial Cited December 7 2018.

41. Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Current Opinion in HIV and AIDS. 2015; 10(5): 374–380. https://doi.org/10.1097/COH.0000000000000179 PMID: 26248124
45. Hoornenborg E, Achterbergh RCA, Schim van der Loeff MF, Davidovich U, Hogewoning A, de Vries HJC, et al. MSM starting pre-exposure prophylaxis are at risk of hepatitis C virus infection: AIDS. 2017; 31(11): 1603–1610. https://doi.org/10.1097/QAD.0000000000001522 PMID: 28657964

46. Hagan H, Jordan AE, Neurer J, Cieland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS. 2015; 29: 2335–2345. https://doi.org/10.1097/QAD.0000000000000834 PMID: 26258525

47. Mayer KH, Crawford P, Dant L, Gillespie S, Singal R, Vandermeer M, et al. HIV and Hepatitis C Virus Screening Practices in a Geographically Diverse Sample of American Community Health Centers. AIDS Patient Care STDS. 2016; 30: 237–246. https://doi.org/10.1089/apc.2015.0314 PMID: 27286294

48. Pereira M, Fialho R. Assessment of factors associated with the quality of life of patients living with HIV/HCV co-infection. J Behav Med. 2016; 39: 767–781. https://doi.org/10.1007/s10865-016-9778-y PMID: 27506910

49. Berenguer J, Gil-Martin A, Jarrin I, Moreno A, Dominguez L, Montes M, et al. All-Oral Direct-Acting Anti-viral Therapy Against Hepatitis C Virus (HCV) in Human Immunodeficiency Virus/HCV-Coinfected Subjects in Real-World Practice: Madrid Co-infection Registry Findings. Hepatology. 2018; 68(1): 32–47. https://doi.org/10.1002/hep.29814 PMID: 29377274

50. Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: The TriP Health Study. J Viral Hepat. 2017; 24: 22–27. https://doi.org/10.1111/jvh.12611 PMID: 27730717

52. Kattakuzhy S, Mathur P, Gross C, Silk R, Akoth E, Hill K, et al. High SVR in PWID with HCV Despite Imperfect Medication Adherence: Data from the Anchor Study. Hepatology. 2018; 68(suppl 1). AASLD Meeting abstract 18.

53. Dore G, Grebely J, Altice F, Litwin AH, Dalgard O, Gain E, et al. HCV Reinfec tion and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Patients on Opioid Agonist Therapy: C-Edge CoSTAR Part B. Hepatology. 2018; 68(suppl 1). AASLD Meeting abstract 52.

54. Doyle JS, Grebely J, Spelman T, Alavi M, Matthews GV, Thompson AJ, et al. Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. PLoS One. 2016; 11(6): e0150655. Published 2016 Jun 29. https://doi.org/10.1371/journal.pone.0150655 PMID: 27355323

55. Ward JW. Strategies for expanding access to HBV and HCV testing and care in the United States: The CDC Hepatitis Testing and Linkage to Care Initiative, 2012–2014 Public Health Rep. 2016 May-Jun; 131(Suppl 2): 1–4.

56. Jayaweera D, Althoff K, Eron J, Huhn G, Milligan S, Mills A, et al. Untreated HCV in HIV/HCV Co-infected in the Real World? Clin Infect Dis. 2016; 62: 919–926. PMID: 26743093